Cancer and Leukemia Group B @ ( Alliance ) randomly assigned @,@ patients with stage III colon cancer to postoperative weekly adjuvant bolus @-fluorouracil/leucovorin ( FU/LV ) or irinotecan + FU/LV ( IFL ) , with @ year follow-up .